Exploring Regorafenib and Nivolumab as Treatment for Colorectal Cancer

(1:4)

Dr. Lenz on Choosing Between Regorafenib and TAS-102 in CRC

(1:12)

Panitumumab, Regorafenib, and Ziv-aflibercept in Metastatic Colorectal Cancer

(11:36)

Regorafenib and pembrolizumab in pre-treated hepatocellular carcinoma

(1:49)

Dr. Bekaii Saab Compares Toxicities of Regorafenib and TAS-102 in Colorectal Cancer

(2:24)

Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment

(1:16)

Regorafenib and TAS102 Synergize Against Gastrointestinal Cancers | Oncotarget

(2:33)

Regorafenib and PD-1 inhibitor for a Sorafenib-Refractory HCC patient - Video abstract [ID 284092]

(2:22)

Dr. Overman on Distinctions Between Regorafenib and TAS-102 in CRC

(1:28)

The rationale for combining regorafenib with IO to treat patients with refractory MSS-CRC

(1:23)

Prior RT may potentially enhance treatment of MSS-CRC with regorafenib and pembrolizumab

(6:56)

Dr. Bekaii-Saab on Differences Between Regorafenib and TAS-102 in CRC

(2:22)

Dr. Bekaii-Saab on Sequencing Regorafenib and TAS-102 in CRC

(1:50)

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

(1:35)

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

(51)

Regorafenib in Advanced Colorectal Cancer: Dosing Strategies

(8:26)

Alan Venook, MD on integrating regorafenib and trifluridine into the 2nd line treatment of mCRC

(25)

Metastatic colorectal cancer: trifluridine/tiripacil or regorafenib?

(2:52)

Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC

(36)

Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy

(32)